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Abstract The use of biotechnology-derived medicines has
significantly increased in recent decades. Although
biosimilars undergo rigorous characterization as well as clin-
ical studies to document their safety and effectiveness, they
are highly complex molecules and small changes in the puri-
fication and production process of a biosimilar can have major
implications in its safety and effectiveness profile. In Latin
America, regulatory authorities have begun to establish well-
described and standardized pathways that permit a biosimilar
to gain commercial licensure. In order to be certain that a
biosimilar reaches its potential in ordinary clinical use, an in-
tensive post-licensing monitoring system must be established
since it is the onlymeans to ascertain the true similarity between
the original biologic and its biosimilar. Pharmacovigilance al-
lows national authorities to determine a drug’s performance in
the marketplace. An effective tracking and pharmacovigilance
system for biological medicines has many steps and processes.
To aid policy makers in Latin American in addressing the many
issues surrounding the establishment of an effective
pharmacovigilance system, the Americas Health Foundation
convened a group of experts to discuss the topic and develop
recommendations for implementation. The group discussed
current challenges and gaps in pharmacovigilance in Latin
America, paying close attention to the major issues associated
with traceability and pharmacovigilance of biosimilars follow-
ing their approval. The recommendations developed should
enable countries to accurately document the safety and perfor-
mance of a biosimilar as experienced by patients under real-life
conditions and have a significant impact on the successful im-
plementation of pharmacovigilance of biosimilars throughout
the region.
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Introduction
The use of biotechnology-derived medicines has increased
dramatically in recent decades. As these products have come
off patent protection, presumed biochemical and therapeuti-
cally equivalent products have been developed and have been
termed biosimilars [1]. That is, a biosimilar is a biologic prod-
uct that can be expected to produce the same therapeutic effect
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in any given patient had the original, or innovator, biologic
medicine been given. Thus, biosimilars are considered to be
similar in efficacy and safety to their reference products and as
such are gaining widespread acceptance as suitably inter-
changeable medicines [2].
Although biosimilars undergo rigorous characterization as
well as clinical studies to document their safety and effective-
ness, the fact remains that they are highly complex biological
molecules. Small changes in the production and purification
process of a biological can have major implications in its
safety and effectiveness profile [3]. Therefore, not only is
thorough pre-clinical and clinical testing critical but demon-
strating the true similarity of a biosimilar to its original product
also requires careful documentation in post-marketing studies.
The ability to trace and track a medicine introduced into the
marketplace is essential. When given to large numbers of pa-
tients, it is not uncommon to document safety issues that were
not seen in the controlled trials necessary for licensure. This is
particularly important for biosimilars because of their multi-
faceted manufacturing processes and because, as stated above,
it is not unreasonable to expect that there may be subtle dif-
ferences in composition between a biosimilar and its reference
product. Such differences may be revealed in an altered safety
and effectiveness profile that is only detected when the med-
icine gains widespread use.
In Latin America, regulatory authorities have begun to es-
tablish well-described and standardized pathways that allow a
biosimilar to gain commercial licensure [1, 4]. In order to be
certain that a biosimilar achieves its potential in ordinary clin-
ical use, an intensive post-licensing monitoring system must
be established since it is the sole means to ascertain the true
similarity between the original biologic and its biosimilar. Un-
fortunately, few Latin American countries have such systems
actively working to capture the relevant information.
Pharmacovigilance (also known as surveillance) allows na-
tional authorities to determine a drug’s performance in the
marketplace. The first component of an effective
pharmacovigilance system is the ability to track the medicine
from manufacture to distribution to prescription. Then, there
must be a system of pharmacovigilance that encourages and is
able to document all adverse events that may be associated
with the use of the medicine. Finally, the data derived from
such reports must be carefully analyzed and reported to health
professionals as well as to the manufacturer [5–7].
An effective tracking and pharmacovigilance system for
biological medicines has many steps and processes. To aid
policy makers in Latin American countries in addressing the
major issues surrounding the establishment of an effective
pharmacovigilance system, the Americas Health Foundation
convened a group of experts to discuss the topic and develop
recommendations for implementation. The group discussed
the current challenges and gaps in pharmacovigilance in Latin
America, paying close attention to the major issues associated
with the traceability and pharmacovigilance of biosimilars
following their approval. The recommendations presented be-
low should enable countries to document accurately the safety
and performance of a biosimilar as experienced by patients
under real-life conditions.
Naming
The name of the product is the foundation of product identi-
fication and is therefore absolutely essential for accurate re-
cord keeping and the subsequent attribution of adverse events.
Currently, under the WHO’s International Nonproprietary
Name (INN) policy, the INN for a new biosimilar may be
the same as that of the original biologic medicine. In such a
case, if only the INN, without a distinguishable identifier, is
used when prescribing a biologic medicine, an adverse event
may be difficult to attribute to a specific product. It
would then be unclear what medicine caused the ad-
verse event, leading to a diminished ability to document
long-term product safety [8, 9].
There is a sharp divide on the issue of the name given to a
biosimilar with some stakeholders calling for biosimilars to be
assigned the same INN as their reference biologic. These in-
dividuals believe that a biosimilar is equivalent to a generic
drug and thus want biosimilars treated as generics, which
means they would have the same INN as the reference prod-
uct. Others suggest the use of distinct propriety names or
nomenclature. Their claim is that a biosimilar is not, and can-
not be, identical to the reference product and thus requires a
unique identifier. Moreover, looking toward the day when
multiple biosimilars are related to one reference product, the
use of identical INNs could lead to inadvertent switching at
the pharmacy and the inability to establish the root cause of
any adverse effects associated with a particular medi-
cine. Faced with a unique INN, however, the inadver-
tent switching of products between patients at pharma-
cies can be avoided, thereby improving traceability and
improving pharmacovigilance.
The use of distinct brand names may help to distinguish
between products. All biosimilar products in the European
Union have a distinct brand name, and many stakeholders
have suggested that the use of distinct brand names for
biosimilars will eliminate the need for distinct non-
proprietary names [10]. However, not all jurisdictions have
the authority to require that products bear a brand name. For
example, in the USA, FDA does not have explicit statutory
authority to require that all biosimilars have a distinct brand
name. In some Latin America countries (e.g., Colombia), cli-
nicians are obligated to prescribe drugs in the public health
system using only the INN. In Brazil, for example, prescrip-
tions may not have brand names in the SUS (SistemaUnico de
Saúde). Thus, the use of distinct non-proprietary names
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becomes critical to distinguish biosimilars from their reference
products. In summary, either a distinct brand name or a dis-
tinct non-proprietary name is crucial in order to implement
effective pharmacovigilance.
Traceability
Biosimilars are not generic products. Unlike with generics,
there may be subtle differences between biosimilars from dif-
ferent manufacturers or a biosimilar compared to its reference
product. To differentiate between medicines, an adverse event
must be traceable to a specific biological product. Thus, clear-
ly identifying the specific biological product being given to a
patient is critical to pharmacovigilance monitoring.
Traceability is a set of procedures that follows the manu-
facture, distribution, and prescription of medicines throughout
the supply chain by means of a well-documented identifica-
tion system.While traceability is often not considered part of a
pharmacovigilance program, in fact, effective traceability
strategies are essential to improved pharmacovigilance. Thus,
traceability is critical to protecting patient safety because
health authorities need accurate data linking adverse events
to specific medicines [11]. As awareness of the benefits of
having an accurate and complete tracing system has become
apparent, efforts have been directed toward making traceabil-
ity a regulatory requirement and developing approaches to
enable and facilitate the implementation of traceability. Ulti-
mately, the traceability of biosimilars is essential to satisfying
basic clinical and public health needs. On the subject of trace-
ability, four main issues are critical: (1) naming, (2) record
keeping, (3) recall mechanisms, and (4) the drug origin. Of
these, naming has been the most controversial and unclear.
Pharmacovigilance
Pharmacovigilance is the science of collecting, monitoring,
assessing, and evaluating information from healthcare pro-
viders and patients on adverse effects or any other drug-
related problem to protect patient safety. The overall goal of
post-marketing is to accurately and promptly trace a patient’s
adverse event to a particular product and manufacturer [7].
Proper labeling, product tracking and a standardized opera-
tional system of pharmacovigilance, and attributing adverse
events are al l components of a well-functioning
pharmacovigilance program.
The main issues involved in monitoring the safety and ef-
fectiveness of a commercial pharmaceutical are as follows:
& Identifying the patient receiving the drug. Monitoring the
patient over time for adverse reactions and the effective-
ness of the product.
& Substitution or interchangeability




The prescription itself serves as a record of who receives a
drug, the dose and frequency of administration and potentially
the indication for its use. Therefore, the prescription itself can
serve as the initial step in a pharmacovigilance program.
When an adverse event occurs, it is then easier for a physician
to relate the event to a specific drug.
Substitution
Substitution occurs when a drug is dispensed that is not the
drug prescribed. In other words, in the case of biologics, sub-
stitution is construed as the legal authority for a hospital or a
pharmacy filling a prescription to switch from dispensing the
innovator product to a biosimilar or the reverse. Substitution
of generic drugs for reference drugs is uncontroversial be-
cause the two will be identical if they have demonstrated bio-
equivalence. However, the issue becomes more complex
when considering the substitution of biosimilars. While
biosimilars are similar to the originator drugs, as mentioned
above, they are not identical and therefore there is currently no
scientific basis to substitute different products. At this time,
regulatory decisions concerning substitution are currently left
to individual countries [12]. For example, the EMA does not
have the authority to designate a biosimilar as automatically
substitutable. The recent trend in Latin America is toward the
adoption of accepted international standards [13].
A lack of clear guidelines on this issue and the consequence
of substitution of one biological medicine for another can
severely impact patient safety and make post-marketing
pharmacovigilance more difficult. The issue of substitution
is also closely tied to naming because if doctors prescribe
biologics by a unique identifier, rather than the currently used
INN, substitution of a biosimilar product when dispensed by a
pharmacist would likely occur much less often. Also, in Latin
America, another concern is related to adverse effects that may
occur when patients are switched back and forth between the
innovator and the biosimilar or even the intended copy [14].
Biosimilars are considered interchangeable if a therapeuti-
cally equivalent biologic can be prescribed by a physician in
place of its reference product [15, 16]. According to the FDA’s
Biologics Price Competition and Innovation Act (BPCIA), Bto
meet a higher standard of Binterchangeability,^ an applicant
must provide sufficient information to demonstrate
biosimilarity, and also to demonstrate that the biological prod-
uct can be expected to produce the same clinical result as the
reference product in any given patient and, if the biological
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product is administered more than once to an individual, the
risk in terms of safety or diminished efficacy of alternating or
switching between the use of the biological product and the
reference product is not greater than the risk of using the
reference product without such alternation or switch..^
Extrapolation of Indication
In some circumstances when a biologic has been shown to be
similar to its reference product, and approved for the same
indication, some experts allow an extrapolation of indication
to those of the reference product. This seems acceptable if the
other diseases for which the reference product is indicated are
truly similar. Also, if clinical similarity can be shown in a key
indication, extrapolation of efficacy and safety data to other
indication(s) of the reference product may be possible, if the
relevant mode of action and/or the receptor(s) involved in the
extrapolated indications are the same.
Data Collection, Analysis, and Reporting
One of the primary weaknesses of current pharmacovigilance
programs is that they are based on sparse and incomplete
reporting. This does not allow for proper ascertainment of
the total number of people exposed to the drug and the rate
and nature of adverse events, making it difficult to estimate the
magnitude of risk and to analyze the root causes of adverse
drug reactions. Pharmacovigilance should go beyond adverse
drug reaction reporting because drugs should also be moni-
tored for their effectiveness (i.e., some drugs have been with-
drawn due to poor risk-benefit ratios). Moreover, in addition
to biosimilars, some reference products have also been asso-
ciated with adverse drug reactions, which necessitate their
inclusion in any intensive pharmacovigilance program.
The development of a pharmacovigilance system should be
based on risk balancing strategies rather than simply reacting
to adverse events. A Risk Management Plan (RMP) [17],
developed by the manufacturer, increases the likelihood that
the benefits of a medicine exceed its risks by the greatest
achievable margin.
A RMP is a set of activities and interventions designed to
identify, characterize, and manage the risks relating to the use
of a medicine. It consists of the following:
& an overview of the safety profile of the medicine
& a pharmacovigilance plan, and
& a risk-minimization plan.
Thus, the RMP is a document describing the risk manage-
ment of a drug from its development to its commercial use. In
addition, the RMP aims to evaluate the drug at regular
intervals (e.g., every 6 months) or in response to post-
marketing pharmacovigilance reports. In submitting adverse
event reports to the manufacturer and/or national authorities,
health professionals should ensure that they clearly identify
the product suspected to have caused the adverse event. Since
the RMP covers the entire life cycle of the product, it should
be periodically updated to reflect new knowledge and under-
standing of the safety profile of the product. Sharing the in-
formation among medical professionals is meant to ensure
further enhancements of post-marketing safety measures.
RMPs also include information on the following:
& a medicine’s safety profile,
& how its risks will be prevented or minimized in patients,
& plans for studies and other activities to gain more knowl-
edge about the safety and efficacy of the medicine,
& risk factors that are related to side effects, and
& measuring the effectiveness of risk-minimization measures.
Recommendations
& Naming:
– Regulatory authorities should consider adopting non-
proprietary names or unique identifiers for biosimilars.
& Traceability:
– Pharmacovigilance legislation should stress the impor-
tance of traceability, and all countries in Latin
America should implement activities to improve
traceability [11, 18].
– Given the importance of accurate identification of pre-
scribed biologics and biosimilars, in order to support
pharmacovigilance monitoring, all medicinal products
must be clearly defined by the use of a specific identifier.
– Each biosimilar should have a unique identifier that is
standard across the region. One approach is to use the
manufacturer’s name in order to differentiate the
biosimilar from the reference product.
– The unique identifier should be included in adverse reac-
tion reporting.
& Substitution and Interchangeability:
– If a product is interchangeable with another, the implica-
tion is that both have been shown to have similar safety
and effectiveness. If that’s the case, substituting one for
another is acceptable. If, however, there is some doubt
about their similarity, then only a physician should autho-
rize substitution of one product for another.
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& Data Collection, Analysis, and Reporting:
– The pharmacy should report all dispensing information to
national authorities. The national authority should collect
at least the following information in each prescription for
biologics being filled by pharmacies:




– All potential drug side effects or adverse effects should be
reported to national authorities by a health professional
and all reported data should go to the national
pharmacovigilance/pharmacovigilance agency
– National pharmacovigilance authorities should evaluate
data received on a regular basis and analyzed data (spe-
cifically pertaining to adverse events) should be publicly
reported on a regular basis
– In order to facilitate the reporting of data regarding bio-
logical medicines to national pharmacovigilance
agencies:
Online reporting should be established
Medical schools should emphasize the importance of
pharmacovigilance, which should be supported by na-
tional societies.
Governments should actively and regularly promote
pharmacovigilance
& Currently, most countries in Latin America have multiple
agencies or organizations receiving adverse event reports.
These multiple systems should be integrated into one na-
tional pharmacovigilance system so that there is a single
database in which all adverse events are captured [19].
& All Latin American countries should establish a certifica-
tion program in order to train pharmacovigilance experts.
Such experts would be trained to manage all aspects of a
country’s data collection and/or analysis related to the use
of pharmaceuticals. The successful implementation of
new and better pharmacovigilance systems requires that
health professionals and regulatory agencies be
trained in the need, value, and operation of the
country’s Bpharmacovigilance system.^ This requires
continuing education about pharmacovigilance pro-
cesses and procedures, as well as changing behavior
by increasing awareness of the importance of
pharmacovigilance.
& The development of a Risk Management Plan should be
mandatory for all biological products.
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